OPKO Health Inc (OPK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
114
About the Report
About the Report
Summary
OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company's product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It offers its diagonostics and therapeutics that are used in the treatment of chronic kidney disease, obesity, asthma, chronic obstructive pulmonary disease (COPD), cancer and chemotherapy-induced nausea and vomiting, among others. It also offers neutraceuticals and veterinary products.The company also offers contract research services to other pharmaceutical companies. The company has its operational presence with its offices located in Chile, Mexico, Spain, Ireland, Canada and Israel. OPKO is headquartered in Miami, Florida, the US.
OPKO Health Inc (OPK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
OPKO Health Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
OPKO Health Inc, Pharmaceuticals & Healthcare, Deal Details 18
Venture Financing 18
Eloxx Pharma Raises Additional USD8 Million in Series C Venture Financing 18
Eloxx Pharma Raises Additional USD6 Million in Series C Financing 20
Partnerships 21
Transition Therapeutics Enters into Agreement with Brigham and Women's Hospital 21
BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 22
Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 23
Licensing Agreements 24
Japan Tobacco Enters into Licensing Agreement with EirGen Pharma 24
Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 25
OPKO Health Enters into Licensing Agreement with Scripps Research Institute 26
Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 27
Opko Health Enters into Licensing Agreement with Pfizer 28
Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 30
OPKO Health Enters Into Licensing Agreement With ChromaDex 31
Opko Health Enters into Licensing Agreement with DSG 32
Transition Therapeutics and Eli Lilly Amend Licensing Agreement 33
Opko Health Enters Into Licensing Agreement With Pharmsynthez 35
Opko Health Enters Into Licensing Agreement For Ranibizumab 37
OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 38
OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 39
Equity Offering 40
Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 40
Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 41
VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 43
Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 45
Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 47
MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 48
Transition Therapeutics Raises USD23 Million in Public Offering of Shares 50
Transition Therapeutics Raises USD17 Million in Private Placement of Units 51
BioZone Pharma Completes Private Placement Of Shares For USD 2.8 Million 53
Arno Therapeutics Completes Private Placement Of Units For USD 30.7 Million 54
Farmsintez Announces Private Placement Of Shares For USD 32.9 Million 56
Transition Therapeutics Completes Private Placement Of Shares For USD 11 Million 57
RXi Pharma Completes Private Placement Of Shares For USD 16 Million 58
Prolor Biotech Completes Public Offering Of Common Stock For USD 37 Million 59
ChromaDex Completes Private Placement Of Common Stock For USD 3.7 Million 61
Debt Offering 63
OPKO Health Raises USD55 Million in Public Offering of 5% Notes Due 2023 63
Opko Health Completes Private Placement Of Notes Due 2033 For USD 175 Million 64
Asset Transactions 66
RXi Pharma Acquires RNAi-Related Assets from Opko Health 66
Acquisition 68
OPKO Health Acquires 5.11% Stake in RXi Pharma 68
OPKO Health Acquires Transition Therapeutics for USD60 Million 69
OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 70
Opko Health Acquires Bio-Reference Labs 71
OPKO Health Acquires EirGen Pharma for USD135 Million 73
Opko Health Acquires Inspiro Medical 74
Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 75
Opko Health Completes Acquisition Of Laboratorio Arama 76
Opko Health Completes Acquisition Of Prolor Biotech For Up To USD 480 Million 77
BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 79
BioReference Labs Acquires Hunter Labs 80
Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 81
Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 82
Opko Health Completes Acquisition Of Silcon Comercio 84
Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For USD 40 Million 85
Opko Health Acquires 45% Stake In SciGen Israel From FDS Pharma 86
OPKO Health Completes Acquisition Of ALS Distribuidora For USD 4 Million 87
SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For USD 25.3 Million 88
OPKO Health Inc-Key Competitors 89
OPKO Health Inc-Key Employees 90
OPKO Health Inc-Locations And Subsidiaries 91
Head Office 91
Other Locations & Subsidiaries 91
Recent Developments 94
Financial Announcements 94
Aug 07, 2018: Opko Health announces second quarter 2018 financial results 94
May 08, 2018: OPKO Health Announces First Quarter 2018 Financial Results 95
Mar 01, 2018: OPKO Health Reports 2017 Fourth Quarter Business Highlights and Financial Results 97
Nov 08, 2017: OPKO Health Reports 2017 Third Quarter Highlights and Financial Results 99
Aug 08, 2017: OPKO Health Reports Second Quarter 2017 Business and Financial Results 100
May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 102
Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 103
Corporate Communications 105
Jan 26, 2018: OPKO Health Announces Resignation Of Gregory Henderson As President Of BioReference Laboratories 105
Sep 06, 2017: Sandra Cole Appointed Vice President and Chief Compliance Officer for OPKO's BioReference Laboratories 106
Aug 21, 2017: Update: Victoria Laughman Named Executive Vice President of Sales for OPKO's BioReference Laboratories 107
Feb 07, 2017: OPKO Health names new chief commercial officer for renal division 108
Legal and Regulatory 109
Sep 07, 2018: SEC Charges Microcap Fraudsters for Roles in Lucrative Market Manipulation Schemes 109
Government and Public Interest 110
Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD 110
Product Approvals 111
Mar 22, 2017: OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 111
Mar 08, 2017: OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 112
Clinical Trials 113
Nov 27, 2017: OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy 113
Appendix 114
Methodology 114
About GlobalData 114
Contact Us 114
Disclaimer 114
List of Figure
List of Figures
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12
List of Table
List of Tables
OPKO Health Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
OPKO Health Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
OPKO Health Inc, Deals By Therapy Area, 2012 to YTD 2018 10
OPKO Health Inc, Medical Devices Deals, 2012 to YTD 2018 12
OPKO Health Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Eloxx Pharma Raises Additional USD8 Million in Series C Venture Financing 18
Eloxx Pharma Raises Additional USD6 Million in Series C Financing 20
Transition Therapeutics Enters into Agreement with Brigham and Women's Hospital 21
BioReference Labs Enters into Co-Development Agreement with Vanderbilt-Ingram 22
Prolor Biotech Plans To Enter Into Commercialization Agreement For Longer-Acting Growth Hormone 23
Japan Tobacco Enters into Licensing Agreement with EirGen Pharma 24
Vifor Fresenius Medical Care Renal Pharma Enters into Licensing Agreement with OPKO Health for Rayaldee 25
OPKO Health Enters into Licensing Agreement with Scripps Research Institute 26
Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 27
Opko Health Enters into Licensing Agreement with Pfizer 28
Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 30
OPKO Health Enters Into Licensing Agreement With ChromaDex 31
Opko Health Enters into Licensing Agreement with DSG 32
Transition Therapeutics and Eli Lilly Amend Licensing Agreement 33
Opko Health Enters Into Licensing Agreement With Pharmsynthez 35
Opko Health Enters Into Licensing Agreement For Ranibizumab 37
OPKO Health Enters Into Licensing Agreement With Scripps Research Institute For SR 3306 38
OPKO Health Enters Into Licensing Agreement With BioZone Pharma For Drug Delivery Platforms 39
Cocrystal Pharma Raises USD3 Million in Private Placement of Shares 40
Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 41
VBI Vaccines Raises USD13.6 Million in Private Placement of Shares 43
Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 45
Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 47
MabVax Therapeutics Raises USD11.6 Million in Private Placement of Units 48
Transition Therapeutics Raises USD23 Million in Public Offering of Shares 50
Transition Therapeutics Raises USD17 Million in Private Placement of Units 51
BioZone Pharma Completes Private Placement Of Shares For USD 2.8 Million 53
Arno Therapeutics Completes Private Placement Of Units For USD 30.7 Million 54
Farmsintez Announces Private Placement Of Shares For USD 32.9 Million 56
Transition Therapeutics Completes Private Placement Of Shares For USD 11 Million 57
RXi Pharma Completes Private Placement Of Shares For USD 16 Million 58
Prolor Biotech Completes Public Offering Of Common Stock For USD 37 Million 59
ChromaDex Completes Private Placement Of Common Stock For USD 3.7 Million 61
OPKO Health Raises USD55 Million in Public Offering of 5% Notes Due 2023 63
Opko Health Completes Private Placement Of Notes Due 2033 For USD 175 Million 64
RXi Pharma Acquires RNAi-Related Assets from Opko Health 66
OPKO Health Acquires 5.11% Stake in RXi Pharma 68
OPKO Health Acquires Transition Therapeutics for USD60 Million 69
OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 70
Opko Health Acquires Bio-Reference Labs 71
OPKO Health Acquires EirGen Pharma for USD135 Million 73
Opko Health Acquires Inspiro Medical 74
Perrigo To Acquire 7% Stake In Transition Therapeutics For USD 15 Million 75
Opko Health Completes Acquisition Of Laboratorio Arama 76
Opko Health Completes Acquisition Of Prolor Biotech For Up To USD 480 Million 77
BioReference Labs To Acquire Edge Bioserv From Edge BioSystems 79
BioReference Labs Acquires Hunter Labs 80
Opko Health Acquires 10% Stake In Pharmsynthez, Life Science Company 81
Opko Health Completes Acquisition Of Cytochroma For Up To USD 290 Million 82
Opko Health Completes Acquisition Of Silcon Comercio 84
Opko Health Completes Acquisition Of Oppenheimer Urologic Reference Laboratory For USD 40 Million 85
Opko Health Acquires 45% Stake In SciGen Israel From FDS Pharma 86
OPKO Health Completes Acquisition Of ALS Distribuidora For USD 4 Million 87
SPIMACO Acquires 48% Stake In EirGen Pharma, Manufacturer Of Cytotoxic Pharmaceutical Products, For USD 25.3 Million 88
OPKO Health Inc, Key Competitors 89
OPKO Health Inc, Key Employees 90
OPKO Health Inc, Other Locations 91
OPKO Health Inc, Subsidiaries 91
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.